Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metformin

P M Bell1, D R Hadden

  • 1Royal Victoria Hospital, Belfast, United Kingdom.

Endocrinology and Metabolism Clinics of North America
|October 6, 1997
PubMed
Summary
This summary is machine-generated.

Metformin, a potent hypoglycemic agent, effectively manages type II diabetes by increasing insulin sensitivity. While a rare risk of lactic acidosis exists, established guidelines ensure its safe and effective therapeutic use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National Diagnostic Working Group (NDWG) for inertial confinement fusion (ICF)/high-energy density (HED) science: The whole exceeds the sum of its parts.

The Review of scientific instruments·2023
Same author

The dilation aided single-line-of-sight x-ray camera for the National Ignition Facility: Characterization and fielding.

The Review of scientific instruments·2018
Same author

Time resolved detection of two-plasmon decay using three-halves harmonic emission on the National Ignition Facility.

The Review of scientific instruments·2018
Same author

A high-speed two-frame, 1-2 ns gated X-ray CMOS imager used as a hohlraum diagnostic on the National Ignition Facility (invited).

The Review of scientific instruments·2016
Same author

Spatial resolution measurements of the advanced radiographic capability x-ray imaging system at energies relevant to Compton radiography.

The Review of scientific instruments·2016
Same author

Two-color spatial and temporal temperature measurements using a streaked soft x-ray imager.

The Review of scientific instruments·2016
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Metformin, a dimethylbiguanide, was first synthesized in 1929.
  • It gained prominence in 1957 for treating obese type II diabetes patients in Europe.
  • Reintroduced in the 1980s, Metformin demonstrated improved insulin sensitivity, leading to its U.S. clinical adoption.

Purpose of the Study:

  • To review the historical development and clinical application of Metformin.
  • To highlight Metformin's efficacy in managing non-insulin-dependent diabetes mellitus.
  • To address the safety profile and established therapeutic guidelines for Metformin use.

Main Methods:

  • Literature review of Metformin's synthesis, rediscovery, and clinical trials.
  • Analysis of Metformin's pharmacological effects, particularly insulin sensitivity.

Related Experiment Videos

  • Examination of documented risks, such as lactic acidosis, and established safety protocols.

    • Main Results:

    • Metformin is a potent hypoglycemic agent with a long history of use.
    • It effectively increases insulin sensitivity, benefiting obese type II diabetes patients.
    • The risk of lactic acidosis is minimal and well-managed with current guidelines.

    Conclusions:

    • Metformin is a safe and effective medication for managing non-insulin-dependent diabetes mellitus.
    • Established guidelines mitigate the risks associated with Metformin therapy.
    • Metformin remains a valuable therapeutic option in diabetes management.